Charles Explorer logo
🇬🇧

Tumor mutation burden - a clinical oncologist's perspective

Publication at First Faculty of Medicine |
2019

Abstract

Checkpoint inhibitors represents an important part of the available antitumor immunotherapy. However, it seems necessary to select patients with the greatest potential benefit from immunotherapy via combination of predictive biomarkers.

One of the promising predictive markers, which have been evaluated intensively, is tumor mutation burden (TMB). The predictive power of TMB is supported by demonstrated higher efficacy of immuno-oncology in NSCLC, melanomas and bladder cancer with high TMB.

Tumor mutational burden assessment as a predictive biomarker for effective immunotherapy in NSCLC patients has been already verified in phase III clinical trials. Implementing TMB analysis in routine diagnostics is currently limited mainly due to a lack of standardization for TMB calculation and reporting.